Cilazapril: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 23: | Line 23: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
{{ | ==Overview== | ||
'''Cilazapril''' is an [[angiotensin-converting enzyme]] inhibitor ([[ACE inhibitor]]) used for the treatment of [[hypertension]] and [[congestive heart failure]].<ref>{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|isbn=978-3-85200-181-4|language=German}}</ref> It is branded as '''Inhibace''' in Canada and other countries, '''Vascace''' and '''Dynorm''' in a number of European countries, among many other names. None of these are available in the [[United States]] as of May 2010.<ref>Drugs.com: [http://www.drugs.com/international/cilazapril.html Cilazapril]</ref> | |||
Of the eight possible [[stereoisomers]], only the all-''S'' form is medically viable. | |||
Of the eight possible [[stereoisomers]], only the all-''S'' form is medically viable. | |||
==References== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:ACE inhibitors]] | [[Category:ACE inhibitors]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
[[Category:Cardiovascular Drugs]][[Category: | |||
Latest revision as of 20:49, 23 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H33N3O6 |
| Molar mass | 435.514 g/mol |
|
WikiDoc Resources for Cilazapril |
|
Articles |
|---|
|
Most recent articles on Cilazapril |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cilazapril at Clinical Trials.gov Clinical Trials on Cilazapril at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cilazapril
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cilazapril Discussion groups on Cilazapril Patient Handouts on Cilazapril Directions to Hospitals Treating Cilazapril Risk calculators and risk factors for Cilazapril
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cilazapril |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cilazapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure.[1] It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these are available in the United States as of May 2010.[2]
Of the eight possible stereoisomers, only the all-S form is medically viable.
References
- ↑ Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
- ↑ Drugs.com: Cilazapril
- Pages with script errors
- CS1 maint: Unrecognized language
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- ACE inhibitors
- Cardiovascular Drugs
- Drug